Evidence map›Paper›PMID 30284232›Full record

ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2019

Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology.

C Grávalos, O Sanmartín, A Gúrpide, A España, M Majem, H J Suh Oh, I Aragón, S Segura, C Beato, R Botella

Open access · hybridAbstract readReviewConsensus Statement
PubMed Publisher
In one paragraph

Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 3 pooled it
1.6field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 3 syntheses or guidelines pooled it, 41 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Observational
  18. Immune-related cutaneous adverse events due to checkpoint inhibitors.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2021
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 9 institutions in 1 country.

C GrávalosMedical Oncology Department, Hospital Universitario 12 de Octubre, Avenida de Córdoba km 5.4, 28041, Madrid, Spain. cgravalos@telefonica.net.ORCID http://orcid.org/0000-0001-9239-6505
O SanmartínDermatology Department, Instituto Valenciano de Oncología, Valencia, Spain.
A GúrpideMedical Oncology Department, Clínica Universitaria de Navarra, Pamplona, Spain.
A EspañaDermatology Department, Clínica Universitaria de Navarra, Pamplona, Spain.
M MajemMedical Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
H J Suh OhDermatology Department, Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Spain.
I AragónMedical Oncology Department, Complejo Hospitalario Universitario de Huelva, Huelva, Spain.
S SeguraDermatology Department, Hospital del Mar, Barcelona, Spain.
C BeatoMedical Oncology Department, Hospital Universitario Virgen Macarena, Sevilla, Spain.
R BotellaDermatology Service, Instituto de Investigación Sanitaria La Fe, Valencia, Spain.
Clinica Universidad de Navarra · ESComplejo Hospitalario de Pontevedra · ESFundación Instituto Valenciano de Oncología · ESHospital Del Mar · ESHospital de Sant Pau · ESHospital Universitario 12 De Octubre · ESHospital Universitario Virgen Macarena · ESInstituto de Investigación Sanitaria La Fe · ESUniversidad de Huelva · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Progress in the understanding of many tumors has enabled the development of new therapies, such as those targeted at specific molecules involved in cell growth (targeted therapies) or intended to modulate the immune system (immunotherapy). However, along with the clinical benefit provided by these new treatments, new adverse effects have also appeared. Dermatological toxicities such as papulopustular eruptions, xerosis, and pruritus are common with EGFR inhibitors. Other adverse effects have also been described with PDGFR, BCR-ABL, and MAPK tyrosine kinase inhibitors, antiangiogenic drugs, and inhibitors at immune checkpoints such as CTLA-4 and PD-1/PD-L1. Onset of these adverse effects often causes dose reductions and/or delays in administering the prescribed therapy, which can affect patient survival and quality of life. It is, therefore, important to prevent the occurrence of these adverse effects, or to treat unavoidable ones as soon as possible. This requires cooperation between medical oncologists and dermatologists. This article reviews the various dermatological toxicities associated with targeted therapies and immunotherapies, along with their diagnosis and therapeutic management.

Indexed as

Quality of LifeAntineoplastic AgentsConsensusDermatologyDisease ManagementHumansImmunotherapyMolecular Targeted TherapyNeoplasmsSkin DiseasesSocieties, MedicalVenereologyAntineoplastic AgentsAntiangiogenic drugsAnti-EGFRDermatological toxicityImmune checkpoint inhibitorsMTOR inhibitorsTargeted therapies

Identifiers

PMID30284232
OpenAlexW2895132169

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.